Article Search

Journal of Cancer Prevention

Original Article

J Cancer Prev 2023; 28(2): 53-63

Published online June 30, 2023

© Korean Society of Cancer Prevention

Economic Burden of Cancer for the First Five Years after Cancer Diagnosis in Patients with Human Immunodeficiency Virus in Korea

Yoonyoung Jang1,2 , Taehwa Kim1,3 , Brian H. S. Kim2,4 , Jung Ho Kim5,6 , Hye Seong7 , Youn Jeong Kim8 , Boyoung Park1

1Department of Preventive Medicine, Hanyang University College of Medicine, 2Program in Regional Information, Department of Agricultural Economics and Rural Development, Seoul National University,3Department of Psychology, Sungkyunkwan University, 4Program in Agricultural and Forest Meteorology, Research Institute of Agriculture and Life Sciences, Seoul National University, 5Division of Infectious Diseases, Department of Internal Medicine, and 6AIDS Research Institute, Yonsei University College of Medicine, 7Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, 8Division of Infectious Disease, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea

Correspondence to :
Boyoung Park, E-mail:,

Received: March 19, 2023; Revised: June 14, 2023; Accepted: June 14, 2023

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


This study aimed to estimate the medical cost of cancer in the first five years of diagnosis and in the final six months before death in people who developed cancer after human immunodeficiency virus (HIV) infection in Korea. The study utilized the Korea National Health Insurance Service-National Health Information Database (NHIS-NHID). Among 16,671 patients diagnosed with HIV infection from 2004 to 2020 in Korea, we identified 757 patients newly diagnosed with cancer after HIV diagnosis. The medical costs for 60 months after diagnosis and the last six months before death were calculated from 2006 to 2020. The mean annual medical cost due to cancer in HIV-infected people with cancer was higher for acquired immunodeficiency syndrome (AIDS)-defining cancers (48,242 USD) than for non-AIDS-defining cancers (24,338 USD), particularly non-Hodgkin’s lymphoma (53,007 USD), for the first year of cancer diagnosis. Approximately 25% of the cost for the first year was disbursed during the first month of cancer diagnosis. From the second year, the mean annual medical cost due to cancer was significantly reduced. The total medical cost was higher for non-AIDS-defining cancers, reflecting their higher incidence rates despite lower mean medical costs. The mean monthly total medical cost per HIV-infected person who died after cancer diagnosis increased closer to the time of death. The estimated burden of medical costs in patients with HIV in the present study may be an important index for defining healthcare policies in HIV patients in whom the cancer-related burden is expected to increase.

Keywords: Human immunodeficiency virus, Acquired immunodeficiency syndrome, Neoplasms, Death, Cost of illness


Share this article on :

Most KeyWord